Affimed N.V. (AFMD)
Company Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe.
Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma.
The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society.
The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014.
Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Country | DE |
IPO Date | Sep 12, 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 76 |
CEO | Dr. Shawn M. Leland Pharm.D., R.Ph. |
Contact Details
Address: Technologiepark Heidelberg, DE | |
Website | https://www.affimed.com |
Stock Details
Ticker Symbol | AFMD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001608390 |
CUSIP Number | N01045108 |
ISIN Number | NL0015001ZQ0 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Shawn M. Leland Pharm.D., R.Ph. | Chief Executive Officer |
Dr. Wolfgang Fischer Ph.D. | MD, Chief Operating Officer, Chief Strategy Officer & Member of Management Board |
Alexander Fudukidis | Head of Investor Relations & Director of Investor Relations |
Denise Mueller | Chief Business Officer & Member of Management Board |
Dr. Andreas Harstrick M.D. | Chief Medical Officer & Member of Management Board |
Mary Beth Sandin | Vice President of Marketing & Communications |
Michael Wolf | Head of Finance & Administration |
Prof. Melvyn Little | Founder & Consultant |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Dec 17, 2024 | 6-K | Filing |
Nov 14, 2024 | 6-K | Filing |
Nov 08, 2024 | 424B5 | Filing |
Nov 04, 2024 | F-3 | Filing |
Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 15, 2024 | 6-K | Filing |
Sep 11, 2024 | 6-K | Filing |
Sep 05, 2024 | 6-K | Filing |
Sep 03, 2024 | 6-K | Filing |